Lexicon Pharmaceuticals | LXRX - Zinsaufwendungen Für Schuld





Zinsaufwendungen Für Schuld Veränderung Datum
Abbott USD 42M 2M 2025-12
Acadia Pharmaceuticals USD 0 4.12M 2024-09
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Akebia Therapeutics 4.83M 359.32M 2025-12
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
AstraZeneca USD 484M 181M 2025-12
BioMarin Pharmaceutical USD 2.78M 199K 2025-12
Coherus Biosciences USD 2.25M 76K 2025-12
Eli Lilly USD 114.7M 134.3M 2025-09
Esperion Therapeutics USD 22.64M 585K 2025-12
Halozyme Therapeutics USD 4.91M 615K 2025-12
Illumina USD 25M 0 2025-09
Insmed USD 20.6M 217K 2025-12
Ironwood Pharmaceuticals USD 8.74M 506K 2024-12
J&J USD 18M 290M 2025-09
Lexicon Pharmaceuticals USD 2.03M 124K 2025-12
MacroGenics USD 3.34M 2.54M 2025-09
MannKind USD 13.87M 6.54M 2025-12
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Novartis USD 304M 23M 2025-12
PTC Therapeutics USD 50.58M 2.59B 2025-12
Puma Biotechnology USD 3.37M 11K 2024-06
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
Thermo Fisher Scientific USD 365M 18M 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
United Therapeutics USD 3.1M 100K 2025-12
Vanda Pharmaceuticals 601.14M 23.61M 2025-09